Skip to main content
OpenTrials
Completed

NCT Number: NCT00658775

Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

The purpose of this study is to investigate the efficacy (ie, healing and symptom relief) and safety of Rabeprazole Extended-Release (RAB ER) 50 mg versus Esomeprazole (ESO) 40 mg for the treatment of moderate to severe erosive Gastroesophageal Reflux Disease (eGERD).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Gastroesophageal Reflux Disease (GERD) Deglutition Disorders Digestive System Diseases Esophageal Diseases Esophageal Motility Disorders Gastroesophageal Reflux Gastrointestinal Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

La Plata, Argentina

Loading trial locations.

About this study

This is a multicenter, randomized, double-blind, double-dummy, parallel-group study. Subjects who meet all the inclusion/exclusion criteria will be randomly assigned to 1 of 2 treatment groups, Rabeprazole Extended-Release (RAB ER) 50 mg or Esomeprazole (ESO) 40 mg for the treatment of moderate to severe erosive Gastroesophageal Reflux Disease (eGERD).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

KEY INCLUSION CRITERIA:

  • Male or female, ages 18 to 75 years.
  • History of GERD symptoms for at least 3 months immediately before screening.
  • Heartburn for at least 2 days a week for at least 1 month before screening.
  • Esophageal erosions of LA Grades C or D based on EGD taken within 14 days prior to enrollment.
  • Subjects who are H. pylori negative based on a screening test.
  • Females should be either of non-childbearing potential or of childbearing potential. Females of childbearing potential must have negative pregnancy tests prior to randomization. Female subjects of childbearing potential must agree to use medically acceptable methods of contraception.
  • Subjects must be able to read, write, and understand the language of the symptom diary.

KEY EXCLUSION CRITERIA:

  • Current or a history of esophageal motility disorders.
  • Current or a history of Barrett's esophagus.
  • Current esophageal strictures or esophagitis (known or suspected to be due to etiology other than GERD such as infection or medications).
  • Current or a history of Zollinger-Ellison syndrome and other acid hypersecretory conditions, or current gastric or duodenal ulcer.
  • Current or a history of cancer, with the exception of fully excised skin basal cell carcinoma.
  • Inflammatory bowel disease.
  • Unstable diabetes mellitus.
  • History of esophageal, gastric and duodenal surgery except simple suturing of an ulcer.
  • Subjects who require daily use of nonsteroidal anti-inflammatory drugs (NSAIDs), oral steroids (>= 20 mg/day prednisone or equivalent), or aspirin (> 325 mg/day).

Treatment and study plan

RABEPRAZOLE SODIUM

Drug

Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.

Other names: Aciphex

Esomeprazole

Drug

Esomeprazole 40 mg capsule, once daily for 4-8 weeks.

Primary outcomes

  1. Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks

    Time frame: Baseline and Week 8

    Healing at week 4 or 8 were based on improvement of eGERD of the Los Angeles (LA) classification of esophagitis Grade C or D from Baseline. Classifications include:

    Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present) Grade A: One or more mucosal breaks not more than 5mm in maximum length. Grade B: One or more mucosal breaks more than 5mm in maximum length, but not continuous between the tops of 2 mucosal folds.

    Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference.

    Grade D: Mucosal breaks involving at least 75% of the esophageal circumference.

  2. Percentage of Participants With eGERD Who Achieved Endoscopically-confirmed Healing by 4 Weeks

    Time frame: Baseline and Week 4

    Healing at week 4 or 8 were based on improvement of eGERD of the LA classification of esophagitis Grade C or D from Baseline. Classifications include:

    Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present) Grade A: One or more mucosal breaks not more than 5mm in maximum length. Grade B: One or more mucosal breaks more than 5mm in maximum length, but not continuous between the tops of 2 mucosal folds.

    Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference.

    Grade D: Mucosal breaks involving at least 75% of the esophageal circumference.

Secondary outcomes

  1. Percentage of Participants Who Achieved Diary-recorded Sustained Resolution of Heartburn by Week 4

    Time frame: Week 4

    During the first 4 weeks of the Double-blind Phase, participants were to record heartburn in a daily diary. Participant daily symptoms for the assessment of heartburn was based on a commonly used 4-point Likert scale of none, mild, moderate and severe. A participant was considered achieving sustained resolution of heartburn if the participant had maintained at least 7 consecutive heartburn-free days.

Sponsors and collaborators

Lead sponsor

Eisai Inc.

Industry

Registry information

Official study title

A Randomized, Double-Blind, Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

Important dates

Study start
2008
Primary completion
2009
Study completion
2010
First posted
Apr 15, 2008
Registry last updated
Dec 21, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.